RxDoctor Payments Data

Tomoaki Kato, MD

Transplant Surgery · New York, NYNPI 1629034517

Payments from drug & device makers

What this record shows

The money is spread across several categories — travel and lodging (46.9%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 20 manufacturers reported payments, led by Transmedics, Inc. at 46.9% of the total.

$8,707in general payments, 2019–2025

Across 39 payments — averaging $223.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Transmedics, Inc.$4K
  • Takeda Pharmaceuticals U.S.A., Inc.$3K
  • Intuitive Surgical$312
  • Olympus America Inc.$304
  • Surgical Specialties Corporation (US), Inc. (dba Corza Medical)$202
  • Stryker$172
  • plus $1K from 14 others
$136,872in research payments, 2019–2025

Across 31 payments — averaging $4415.22 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Transmedics, Inc.$74K
  • Grifols Biologicals LLC$55K
  • Grifols Therapeutics LLC$8K

What the payments were for

  • Consulting fees$2,62530%
  • Travel & lodging$4,08147%
  • Food & beverage$2,00123%

General payments by program year

20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,707 in reported general payments places this provider in the 70th percentile of 72 transplant surgery providers in New York.

See all transplant surgery providers in New York

Medicare billing

Part B allowed, 2024
$71,538
Medicare patients
34
Services billed
71

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other transplant surgery in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →